MDACC Study No:2012-0151 ( NCT No: NCT01564784)
Title:An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Principal Investigator:Hagop Kantarjian
Treatment Agent:Cytarabine; Fludarabine; G-CSF; Inotuzumab Ozogamicin; Mitoxantrone
Study Status:Closed
Study Description:The goal of this clinical research study is to compare inotuzumab ozogamicin to
3 other types of chemotherapy treatments when given to patients with relapsed
or refractory ALL. The safety of inotuzumab ozogamicin will also be studied.

Inotuzumab ozogamicin is designed to attach to a protein that is often found in
leukemia cells. This will allow the drug to go inside the cell and may cause
the cancer cells to die.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase III
Treatment Agents:Cytarabine
Inotuzumab Ozogamicin
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Pfizer
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Hagop Kantarjian
For Clinical Trial Enrollment:713-792-7026
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults